Sample6

About:

Sample6 is a synthetic, biology-based bacteria diagnostic system that is capable of enrichment-free detection.

Website: http://phagediagnostics.com

Twitter/X: Sample6tech

Top Investors: Massachusetts Life Sciences Center, Founder Collective, Flybridge, Acre Venture Partners, The Kraft Group

Description:

Sample6 is a synthetic-biology based bacteria diagnostic system capable of enrichment-free detection. Its technology detects as low as 1CFU/ml in just 4 hours. Its proprietary Bioillumination Platform was developed by Professor Tim Lu (MIT) and Dr. Michael Koeris in the lab of Professor James Collins at the Howard Hughes Medical Institute and Boston University. The platform allows for the engineering of bioparticles that target and “light up” specific unwanted bacteria—or specific groups of bacterial species. They couple this capability with highly sensitive sensor technology that detects low levels of pathogens to see results in minutes—right on-site—with no laboratory required. Sample6′s mission is to improve the health and safety of global consumers by building integrated systems that quickly and easily detect harmful and unwanted bacteria. They see applications in food production, retailing, healthcare, and beyond—anywhere humans and bacteria intersect.

Total Funding Amount:

$41.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2009-01-01

Contact Email:

info(AT)sample6tech.com

Founders:

Michael Koeris, Tanguy Chau, Timothy K. Lu, Timothy Lu

Number of Employees:

11-50

Last Funding Date:

2016-08-22

IPO Status:

Private

Industries:

© 2025 bioDAO.ai